Fluorocarbon-Linked Peptide Formulation

Abstract

The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

1 - 27 . (canceled) 
     
     
         28 . A sterile, dried mixture of fluorocarbon-linked peptides, wherein the dried mixture comprises one or more fluorocarbon-linked peptides comprising 20 to 50 amino acid residues linked to a fluorocarbon, at least 50% hydrophobic amino acid residues, an isoelectric point greater than or equal to 7, and one or more T cell epitopes, not comprising a contiguous sequence of 20 amino acid residues comprising more than 80% hydrophobic amino acid residues; and wherein the mixture is in a solid form. 
     
     
         29 . The dried mixture of  claim 28 , wherein the solid form is lyophilized as an amorphous cake or a powder. 
     
     
         30 . The dried mixture of  claim 28 , wherein the solid form is dried by vacuum drying, spray-drying, freeze drying or fluid bed drying. 
     
     
         31 . The dried mixture of  claim 28 , wherein the solid is freeze dried. 
     
     
         32 . The dried mixture of  claim 28 , wherein the mixture is disposed in a vial, an ampoule or a syringe. 
     
     
         33 . The dried mixture of  claim 32 , further comprising a pharmaceutically acceptable carrier. 
     
     
         34 . The dried mixture of  claim 28 , wherein the peptide linked to the fluorocarbon is an immunogenic peptide having a sequence derived from (i) a protein or peptide from a pathogen or tumor cell or (ii) an autologous protein. 
     
     
         35 . The dried mixture of  claim 28 , wherein the one or more T cell epitopes are from a pathogen, an autoimmune protein, or allergen or a tumor antigen. 
     
     
         36 . The dried mixture of  claim 35 , wherein the pathogen is a virus, bacterium, mycobacterium, parasite or fungus. 
     
     
         37 . The dried mixture according to  claim 28 , wherein the fluorocarbon comprises a chain from 3 to 20 carbon atoms, wherein one or more fluorine moieties is optionally replaced with a halogen moiety of Cl, Br, or I; a methyl group; or a hydrogen. 
     
     
         38 . The dried mixture according to  claim 28 , wherein the fluorocarbon comprises the formula C 8 F 17 (CH 2 ) 2 . 
     
     
         39 . The dried mixture according to  claim 28 , wherein the one or more fluorocarbon-linked peptides are present in micelles. 
     
     
         40 . A sterile, dried mixture of fluorocarbon-linked immunogenic peptides, wherein the dried mixture comprises one or more fluorocarbon-linked immunogenic peptides comprising 20 to 50 amino acid residues linked to a fluorocarbon, at least 50% hydrophobic amino acid residues, an isoelectric point greater than or equal to 7, and one or more T cell epitopes, not comprising a contiguous sequence of 20 amino acid residues comprising more than 80% hydrophobic amino acid residues;
 wherein the immunogenic peptides are derived from Hepatitis B virus (HBV); and,   wherein the mixture is in a solid form.   
     
     
         41 . The dried mixture of  claim 40 , wherein the solid form is lyophilized as an amorphous cake or a powder. 
     
     
         42 . The dried mixture of  claim 40 , wherein the solid form is dried by vacuum drying, spray-drying, freeze drying or fluid bed drying. 
     
     
         43 . The dried mixture of  claim 40 , wherein the solid is freeze dried. 
     
     
         44 . The dried mixture of  claim 40 , wherein the mixture is disposed in a vial, an ampoule or a syringe. 
     
     
         45 . The dried mixture of  claim 44 , further comprising a pharmaceutically acceptable carrier. 
     
     
         46 . The dried mixture according to  claim 40 , wherein the fluorocarbon comprises a chain from 3 to 20 carbon atoms, wherein one or more fluorine moieties is optionally replaced with a halogen moiety of Cl, Br, or I; a methyl group; or a hydrogen. 
     
     
         47 . The dried mixture according to  claim 40 , wherein the fluorocarbon comprises the formula C 8 F 17 (CH 2 ) 2 .